Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
Press release, Helsinki, 17May2023 at 2 PM (EEST)
Nexstim’s QualitySystem and NBS 6 Receive MDR Certification in the EU
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received certifications for its quality management system and NBS 6 product under MDR (Regulation (EU) 2017/745) in the European Union.
The EU quality management system certificate allows for Nexstim to start marketing and selling the NBS 6 system for the treatment of major depression and chronic neuropathic pain within the European Union. Nexstim announced on April 17, 2023, that it had launched NBS 6 in the United States for the treatment of Major Depressive Disorder (MDD).
The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or treatment interests.
Mikko Karvinen, CEO of Nexstim, comments:
“The MDR conformity certification is an important step in the process of launching theNBS 6 and achieving one of our keystrategic objectives for 2023. I am proud of the hard work our team has put into making the new software generation available in both the United States and the European Union in such a tight schedule. The EU quality management system certification will benefit us in the long term also by making any future product certification processes more efficient.
The NBS 6 received a great response as we attended and unveiled the product at the Clinical TMS Society Annual Meeting in Colorado Springs, United States earlier this month. We are expecting nothing less from the European market and are excited to continue the promotion work.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 AND THE ORGANIZING MEETING OF THE BOARD OF DIRECTORS25.4.2024 19:00:00 CEST | Press release
DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 AND THE ORGANIZING MEETING OF THE BOARD OF DIRECTORS Digitalist Group Oyj Stock Exchange Release 25 April 2024 at 20:00 DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 Adoption of the financial statements The Annual General Meeting of Digitalist Group Plc (the “Company”) adopted the Company’s financial statements and consolidated financial statements for the financial period 1 January -31 December 2023. Resolution on the use of the loss shown on the balance sheet and on the distribution of assets The Annual General Meeting resolved that the loss EUR 4,575,895.22 indicated by the financial statements for 2023 be recorded in the Company’s profit and loss account, and that no dividend be paid to shareholders for the financial period 2023. Resolution on the discharge of the members of the Board of Directors and the CEO from liability for the financial period 1 January 2023 to 31 December 2023
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC25.4.2024 19:00:00 CEST | Press release
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shares of the then outstanding 9,014,821,287 shares, and therefore crossed below the threshold (5%) by virtue of the sale of voting securities. See Annex 1. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press release may
Heineken Holding N.V. Annual General Meeting of Shareholders adopts all proposals25.4.2024 18:31:00 CEST | Press release
Amsterdam, 25 April 2024 - Heineken Holding N.V. announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions and announcements are listed below. Dividend The Board of Directors announced the distribution of a dividend for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken Holding N.V. shares will be quoted ex-dividend on 29 April 2024. Reappointment of Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors The AGM reappointed Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors for a four-year term. Appointment of External Auditor The AGM appointed KPMG Accountants N.V. as external auditor for the financial year 2025. The voting results per agenda item of the AGM of Heineken Holding N.V. of 25 April 2024 can be found on th
Heineken N.V. Annual General Meeting adopts all proposals25.4.2024 18:30:00 CEST | Press release
Amsterdam, 25 April 2024 - Heineken N.V. (HEINEKEN) announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions are listed below. Re-appointment of Executive Board Member The AGM re-appointed Dolf van den Brink as member of the Executive Board for a period of four years, until the end of the AGM to be held in 2028. Dividend The AGM adopted the dividend proposal for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken N.V. shares will be quoted ex-dividend on 29 April 2024. Re-appointment of Supervisory Board Member The AGM re-appointed Jean-Marc Huët as member of the Supervisory Board for a two-year term. Re-appointment of Supervisory Board Member The AGM re-appointed Pamela Mars Wright as member of the Supervisory Board for a two-year term. Appointment of Supervi
Havila Kystruten AS: Integrated Annual Report for 202325.4.2024 18:04:39 CEST | Press release
The board of directors of Havila Kystruten AS has today approved the financial statements and annual report for 2023, which integrates financial and sustainability reporting. The report is attached in PDF format along with a visual presentation summarizing the year and highlighting the company's fundamental focus on the environment and sustainability. The annual financial statements have been adjusted compared to the preliminary and unaudited result for 2023, which was presented on February 28, 2024. There has been a write-down of the inventory value by NOK 11.2 million, with corresponding effects on the income statement and balance sheet. Further information is available in note 15 of the consolidated financial statements. Contacts: Chief Executive Officer Bent Martini, +47 905 99 650 Chief Financial Officer Aleksander Røynesdal, +47 413 18 114 Attachments HKY_Integrated Annual Report 2023HKY_Integrated Annual Report Presentation 2023HKY_Integrert arsrapport 2023